Cécilia Hindorf

Biodistribution and dosimetry of the carbon-11 labelled PARP1-selective PET radiopharmaceutical [11C]AZ14193391

Anders Törnblom, Cecilia He, Martin Bolin, Antonios Tzortzakakis et autres

Abstract Background Poly (ADP-ribose) polymerase-1 (PARP1) inhibitors are used for treatment of advanced breast, ovarian, and prostate cancer with germline or somatic BRCA1/2 mutations. However, not all patients respond to these drugs, and therapy-predictive biomarkers are needed to optimise the benefit-risk balance. …

se (code pays fourni par la source)

Additional file 1 of Biodistribution and dosimetry of the carbon-11 labelled PARP1-selective PET radiopharmaceutical [11C]AZ14193391

Anders Törnblom, Cecilia He, Martin Bolin, Antonios Tzortzakakis et autres

Additional file 1: Supplementary Figure S1. Individual decay-corrected TAC fit results. Solid lines are individual fits where the same biodistribution model as the parametric bootstrap fit was applied. Dashed lines are individual fits where a different biodistribution model from the parametric bootstrap …

se (code pays fourni par la source)

Additional file 1 of Biodistribution and dosimetry of the carbon-11 labelled PARP1-selective PET radiopharmaceutical [11C]AZ14193391

Anders Törnblom, Cecilia He, Martin Bolin, Antonios Tzortzakakis et autres

Additional file 1: Supplementary Figure S1. Individual decay-corrected TAC fit results. Solid lines are individual fits where the same biodistribution model as the parametric bootstrap fit was applied. Dashed lines are individual fits where a different biodistribution model from the parametric bootstrap …

se (code pays fourni par la source)

First-in-human radiation dosimetry of the GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in patients with prostate and breast cancer

Annie Bjäreback, Ulrika Estenberg, Antonios Tzortzakakis, Rimma Axelsson et autres

Abstract Background Gastrin-releasing peptide receptor (GRPR) is overexpressed in several malignant tumours, while its physiological expression in major organs, except for pancreas, is low. GRPR is therefore an interesting target in nuclear medicine. The GRPR-binding ligand, [ 68 Ga]Ga-NOTA-PEG 2 -RM26 has …

se (code pays fourni par la source)

HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial

Renske Altena, Oscar P. B. Wiklander, Nour Susaeg Romdhani, Anna Kistner et autres

Background: Trastuzumab deruxtecan (T-DXd) is effective in HER2-expressing metastatic breast cancer (mBC), yet inter-patient benefit varies. The current reference biomarker-HER2 immunohistochemistry (IHC) on tumor biopsies-is insufficient as a sole predictor of response. HER2-targeted PET/CT offers non-invasive, whole-body, real-time assessment of target expression. …

se, nz, us (code pays fourni par la source)

654eTiP A multicentre, prospective, open-label study using [68Ga] Ga-ABY-025 PET to assess HER2 expression and predict response to HER2-ADC therapy in metastatic breast cancer

Renske Altena, Oscar P. B. Wiklander, Anna Kistner, Chihebeddine Romdhani et autres

se, nz (code pays fourni par la source)

A validation protocol for 177Lu-SPECT image quantification as a basis for multi-centre kidney dosimetry

Lovisa Jessen, Selma Curkic Kapidzic, Johan Gustafsson, Erik Larsson et autres

Abstract Objective. Multicentre studies in molecular radiotherapy face challenges in ensuring the comparability of dosimetry results. The aim of this study was to develop a validation protocol to achieve equivalent 177Lu-SPECT quantification across centres, consisting of a test exercise in combination with …

se, gb (code pays fourni par la source)

First-in-human experience with GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in prostate and breast cancer patients using PET/CT

Annie Bjäreback, Olof Jonmarker, Antonios Tzortzakakis, Emma Jussing et autres

Gastrin-releasing peptide receptors (GRPR) are overexpressed in many tumors including prostate, breast, and colorectal cancers [ 1 ]. In particular, GRPR are overexpressed in low-grade prostate cancer (PC) and estrogen-positive (ER+) breast cancer (BC) [ 2 , 3 ]. Positron emission tomography …

se (code pays fourni par la source)

Count-rate management in 131I SPECT/CT calibration

Staffan Jacobsson Svärd, Cécilia Hindorf, Joachim N. Nilsson

Abstract Background System calibration is essential for accurate SPECT/CT dosimetry. However, count losses due to dead time and pulse pileup may cause calibration errors, in particular for 131I, where high count rates may be encountered. Calibration at low count rates should also …

se (code pays fourni par la source)

Risk of treatment-altering haematological toxicity and its dependence on bone marrow doses in peptide receptor radionuclide therapy

M. Persson, Cécilia Hindorf, Oscar Ardenfors, Martin Larsson et autres

Abstract Background Peptide receptor radionuclide therapy is effective in treating neuroendocrine tumours, but treatment may be limited by kidney and bone marrow toxicity. In this work, the absorbed dose burden to the bone marrow was estimated using image-based dosimetry and its potential …

se (code pays fourni par la source)

Traceable calibration with 177Lu and comparison of activity meters at hospitals in Norway and Sweden

Cécilia Hindorf, Lovisa Jessen, Selma Curkic Kapidzic, Johan Blakkisrud et autres

se, no (code pays fourni par la source)

Quantitative myocardial perfusion should be interpreted in the light of sex and comorbidities in patients with suspected chronic coronary syndrome - a cardiac positron emission tomography study

A Székely, Katarina Steding‐Ehrenborg, Daniel Ryd, Fredrik Hedeer et autres

Abstract Background and aim Diagnosis and treatment of patients with suspected chronic coronary syndrome (CCS) currently relies on the degree of coronary artery stenosis and its significance for myocardial perfusion (1). However, myocardial perfusion can be affected by factors other than coronary …

se (code pays fourni par la source)